Corrigendum: Association of CTLA-4 Gene Variants With Response to Therapy and Long-Term Survival in Metastatic Melanoma Patients Treated With Ipilimumab: An Italian Melanoma Intergroup Study

Frontiers in Immunology - Switzerland
doi 10.3389/fimmu.2018.00403
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Frontiers Media SA

Related search

Ipilimumab: An Anti-Ctla-4 Antibody for Metastatic Melanoma

Clinical Cancer Research
Cancer ResearchOncology
2011English

Serum Immunoregulatory Proteins as Predictors of Overall Survival of Metastatic Melanoma Patients Treated With Ipilimumab

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2015English

Panhypopituitarism in Metastatic Melanoma Patient Treated With Ipilimumab and Pembrolizumab

Journal of Cutaneous Immunology and Allergy
2019English

Bevacizumab Plus Ipilimumab in Patients With Metastatic Melanoma

Cancer immunology research
Cancer ResearchImmunology
2014English

Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated With Anti-Ctla-4 Antibodies: Association With Overall Survival?

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2013English

Comment on ‘Efficacy and Toxicity of Treatment With the Anti-Ctla-4 Antibody Ipilimumab in Patients With Metastatic Melanoma After Prior Anti-Pd-1 Therapy’

British Journal of Cancer
Cancer ResearchOncology
2017English

Site‐specific Response Patterns, Pseudoprogression, and Acquired Resistance in Patients With Melanoma Treated With Ipilimumab Combined With Anti–PD‐1 Therapy

Cancer
Cancer ResearchOncology
2019English

The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-Ctla-4 Therapy in Metastatic Melanoma From the Ipilimumab Network

PLoS ONE
Multidisciplinary
2013English

Late Development of Splenic Sarcoidosis-Like Lesions in a Patient With Metastatic Melanoma and Long-Lasting Clinical Response to Ipilimumab

OncoImmunology
OncologyAllergyImmunology
2014English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy